**A. PURPOSE**

This grant was created in 2024 to honor Dr. David W. Kennedy, M.D. and his innumerable contributions to the field of Rhinology. The purpose of this award is to support innovative research that moves the field of Rhinology forward and can include non- “traditional” research avenues such as innovations in teaching, development of novel technologies, or new treatment approaches used in Rhinology.

**B. ELIGIBILITY**

Any resident or fellow in training at an accredited program in the U.S. or Canada or a practicing Rhinologist (who must be a member in good standing of the ARS), is eligible to apply for the David W. Kennedy, M.D., Innovation in Rhinology Grant. Resident/fellow applicants must have a supervising faculty ARS member in good standing as a co-investigator. Practicing Rhinologists do not necessarily need to be affiliated with training programs or academic institutions.

**Applicants or their representatives must be able to attend the ARS Summer Sinus Symposium for live presentation of their proposals with Q&A on July 11, 2025, should they be selected as a finalist for the award.**

**Applications submitted by ineligible PIs will NOT be reviewed.**

**C. CONDITIONS**

Proposed projects may be related to any area of Rhinology with extra value given to innovative proposals that may not represent traditional "hypothesis-driven research”. The goal of this award is to support individuals with innovative ideas to make new and important contributions to our field. Preliminary data are not necessarily required, but in this instance a strong rationale should be provided and feasibility demonstrated.

Proposed projects from trainees should be designed in collaboration with a preceptor investigator and approved by the candidate's department chairperson and institution. Applications from trainees must be accompanied by a letter of support from the applicant’s Department Chair and Preceptor verifying that the applicant will be permitted to devote an appropriate amount of time to the conduct and timely completion of the proposed research project. Applicants must obtain letters of support/understanding from all key personnel on the project.

**D. TERMS**

1. **Amount:** $10,000 maximum total costs
2. **Period:** 12 months, non-renewable
3. **Funding:** Applications will be initially reviewed by the ARS Research and Grants Committee, with preference placed on innovation, future potential, feasibility, appropriateness of budget, and likelihood for project completion which may be described with a timeline or defined deliverables. **The top three applicants will be notified in late May 2025, and will be invited to present their projects at an ARS Summer Sinus Symposium special session for a “Shark-Tank” style format with ~10-15 minutes allotted per proposal. Audience response will be used to determine the awardee**. If applicants (or appropriate representatives) are unable to attend and present at SSS, then they will not be eligible for consideration.
4. **Use of Funds:** Funding may not be used for salary support for the Investigator. Any use of funds to support assistants or other technical personnel should be justified.
5. **Notification:** The awardee will be selected at Summer Sinus Symposium.
6. **Start Date:** The grant may be activated upon notification of the award and release of funds, but no later than January 1 of the following year.

**E. FORMAT**

The application is limited to 2 pages and may contain only 1 figure or table. It should be responsive to the grant’s stated purpose and the preferences outlined above in Section D.3.

* Font size must be 11 points or larger. Smaller text in figures, graphs, diagrams and charts is acceptable if it is legible when the page is viewed at 100%
* Margins must be at least ½” for all pages (top, bottom, left, and right)
* Do not use headers/footers
* References may be listed on an additional page using any standard format

**A single PDF must be submitted online through the ARS website by midnight, Eastern Standard Time, May 15, 2025.** **The PDF should include the 2-page application, brief applicant CV (<2 pages), and if applicable, references, support letters, IRB/IACUC statement.**

**F. APPROVALS**

If the proposed research involves human subjects or vertebrate animals, the appropriate FDA, institutional review board (IRB), or animal use and care committee (IACUC) documents should be included. Approvals should be obtained prior to submission but if such approval is not provided, the review committee will consider likelihood of timely approval in their evaluation.

**G. FOLLOW-UP**

In carrying out its stewardship of research programs, the ARS may request information essential to an assessment of the effectiveness of this program. Accordingly, the recipient is hereby notified that s/he may be contacted after the completion of the award for periodic updates on employment history, publications, support from research grants or contracts, honors and awards, professional activities, and other information helpful in evaluating the impact of the program. Of note, the ARS has no interest in intellectual property assignment potentially developed through this program.

**H. REPORTING REQUIREMENTS**

Recipients of the David W. Kennedy, M.D. Innovation in Rhinology Grant are required to complete an interim report at 6-months. Within ~3 months of the completion of the project, the awardee is expected to submit a final report including a financial report of expenses related to the project.

*The results of this work must be submitted for presentation at an ARS national meeting no later than 12 months after completion of the project.* The recipient shall be free to publish the results afterward, but the American Rhinologic Society shall have the right of first refusal for publication in its journal, *The International Forum of Allergy and Rhinology*. Any presentation or publication of results supported by this award shall acknowledge the contribution of the ARS research grant.

**CONTACT**

If you have questions regarding this funding opportunity announcement, please contact Wendi Perez ([wendi@amrhso.org](mailto:wendi@amrhso.org)) at ARS and cc the current Research and Grants Committee Chair, Carol Yan, MD (c1yan@health.ucsd.edu).